DUBLIN--(BUSINESS WIRE)--The "Uveitis Pipeline Highlights - 2017 Update" drug pipelines has been added to Research and Markets' offering.
Uveitis Pipeline Highlights - 2017 Update, provides most up-to-date information on key pipeline products in the global Uveitis market. It covers emerging therapies for Uveitis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Uveitis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Uveitis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
Company:
The report provides Uveitis pipeline products by the company.
Short-term Launch Highlights:
Find out which Uveitis pipeline products will be launched in the US and Ex-US till 2020.
Key Topics Covered:
1. Uveitis Pipeline by Stages
2. Uveitis Pipeline by Drug Class
3. Uveitis Pipeline by Company
4. Uveitis Phase 3 Clinical Trial Insights
5. Uveitis Phase 2 Clinical Trial Insights
6. Uveitis Phase 1 Clinical Trial Insights
7. Uveitis Preclinical Research Insights
8. Uveitis Discovery Stage Insights
9. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7r3vrw/uveitis_pipeline
